Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy

• A.E. Yung,
• Y.J. Jeong,
• A.H. Varey,
• S.N. Lo,
• R. Gupta,
• R. Wu,
• M. Dunn,
• J.H. Lee,
• T.-H.H. Low,
• K.F. Shannon,
• J.R. Clark,
• S. Ch'ng

Affiliations

A.E. Yung

University of Sydney, Sydney, Australia

Y.J. Jeong

Royal Prince Alfred Hospital, Sydney, Australia

A.H. Varey

Melanoma Institute Australia, Sydney, Australia; Westmead Private Hospital, Sydney, Australia

S.N. Lo

University of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia

R. Gupta

University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

R. Wu

Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

M. Dunn

Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

J.H. Lee

Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

T.-H.H. Low

Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

K.F. Shannon

Melanoma Institute Australia, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

J.R. Clark

University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia

S. Ch'ng

University of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia; Chris O'Brien Lifehouse Cancer Centre, Sydney, Australia